X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (530) 530
index medicus (355) 355
animals (332) 332
oncology (233) 233
receptor, epidermal growth factor - antagonists & inhibitors (205) 205
receptor, epidermal growth factor - metabolism (193) 193
female (178) 178
receptor, erbb-4 (174) 174
mice (167) 167
signal transduction (164) 164
cancer (151) 151
growth-factor receptor (140) 140
biochemistry & molecular biology (125) 125
cell biology (120) 120
expression (120) 120
cell line, tumor (118) 118
egfr (106) 106
receptor, epidermal growth factor - genetics (105) 105
receptor, erbb-2 - metabolism (104) 104
receptor, erbb-2 - antagonists & inhibitors (103) 103
epidermal growth factor (102) 102
male (102) 102
antineoplastic agents - therapeutic use (101) 101
antineoplastic agents - pharmacology (99) 99
signal transduction - drug effects (94) 94
phosphorylation (88) 88
neurosciences (78) 78
breast cancer (75) 75
research (75) 75
epidermal-growth-factor (74) 74
care and treatment (73) 73
quinazolines - pharmacology (70) 70
tyrosine kinase inhibitor (70) 70
pharmacology & pharmacy (68) 68
article (67) 67
ligands (66) 66
tyrosine (65) 65
breast-cancer (63) 63
rats (63) 63
signal transduction - physiology (63) 63
protein kinase inhibitors - pharmacology (62) 62
apoptosis (61) 61
kinases (59) 59
proteins (59) 59
antibodies, monoclonal - therapeutic use (58) 58
cell proliferation - drug effects (58) 58
receptor, epidermal growth factor - physiology (56) 56
erbb4 (55) 55
health aspects (55) 55
breast neoplasms - metabolism (54) 54
activation (53) 53
breast neoplasms - drug therapy (53) 53
mutation (53) 53
cell lung-cancer (52) 52
egf receptor (52) 52
protein kinase inhibitors - therapeutic use (51) 51
medicine & public health (50) 50
neuregulin-1 - metabolism (50) 50
enzyme inhibitors - pharmacology (49) 49
neoplasms - drug therapy (49) 49
tyrosine kinase (49) 49
gene expression (48) 48
analysis (47) 47
monoclonal-antibody (47) 47
schizophrenia (47) 47
genetic aspects (46) 46
receptor, erbb-3 - metabolism (46) 46
cells, cultured (44) 44
gefitinib (44) 44
receptor, erbb-2 - genetics (44) 44
biology (43) 43
cell proliferation (43) 43
genetics & heredity (43) 43
protein-tyrosine kinases - antagonists & inhibitors (43) 43
research article (43) 43
monoclonal antibodies (42) 42
phase-ii trial (42) 42
receptors (42) 42
antibodies, monoclonal, humanized (41) 41
apoptosis - drug effects (41) 41
quinazolines - therapeutic use (41) 41
tyrosine kinase inhibitors (41) 41
breast neoplasms - pathology (40) 40
clinical trials as topic (40) 40
neurons (40) 40
physiological aspects (40) 40
tumors (40) 40
cetuximab (39) 39
lung neoplasms - drug therapy (39) 39
cells (38) 38
factor receptor (38) 38
immunohistochemistry (38) 38
trastuzumab (38) 38
cell line (37) 37
epidermal growth factor receptor (37) 37
lung-cancer (37) 37
neuregulin (37) 37
receptor (37) 37
skin and connective tissue diseases (37) 37
tumor cells, cultured (37) 37
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, p. e0178028
Journal Article
Genes, Brain and Behavior, ISSN 1601-1848, 01/2018, Volume 17, Issue 1, pp. 56 - 69
The receptor tyrosine kinase ErbB4 and its ligand trophic factors of the neuregulin (NRG) family have been associated with schizophrenia and other mental... 
5-CSRTT | Behavioral Neuroscience | mouse model | inhibitory control | JNJ-28871063 | schizophrenia | CombiCage | Neurology | Nrg–ErbB4 | executive functions | impulsivity | attention | Genetics | JNJ‐28871063 | 5‐CSRTT | PARVALBUMIN-POSITIVE INTERNEURONS | NERVOUS-SYSTEM | HUMAN BRAIN | SCHIZOPHRENIA-LIKE PHENOTYPES | PREPULSE INHIBITION | NEUROSCIENCES | REACTION-TIME-TASK | Nrg-ErbB4 | GENETIC-VARIATION | 3 NRG3 | NEUREGULIN-1 KNOCKOUT MICE | BEHAVIORAL SCIENCES | ACOUSTIC STARTLE | Receptor, ErbB-4 - metabolism | Schizophrenia - metabolism | Signal Transduction | Mice, Inbred C57BL | Male | Mice, Transgenic | Reaction Time | Fear - physiology | Synaptic Transmission | Attention - physiology | Animals | Schizophrenia - genetics | Neuregulin-1 - metabolism | Attention - drug effects | Mice | Receptor, ErbB-4 - antagonists & inhibitors | Receptor, ErbB-4 - deficiency | Receptor, ErbB-4 - genetics | Memory - physiology | Tyrosine | Schizophrenia | Medicine, Experimental | Medical research | Analysis | Mental disorders | ErbB protein | Channel gating | Hyperactivity | Spatial discrimination learning | Spatial discrimination | Central nervous system | Reaction time task | ErbB-2 protein | Sensorimotor gating | Attention task | Signal transduction | Social behavior | Rodents | Protein-tyrosine kinase receptors | Neuregulin | Trophic factors | Gating | Protein-tyrosine kinase | Spatial memory
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 16, pp. 2275 - 2284
Abstract Background This phase I study evaluated afatinib, an irreversible ErbB family blocker, plus paclitaxel in patients with advanced solid tumours likely... 
Hematology, Oncology and Palliative Medicine | Afatinib | ErbB receptors | Neoplasms | Paclitaxel | Clinical trial phase I | ERBB receptors | BIBW 2992 | ADENOCARCINOMA | OPEN-LABEL | KINASE INHIBITOR | CHEMOTHERAPY | CELL LUNG-CANCER | DOSE-ESCALATION | ONCOLOGY | QUALITY-OF-LIFE | III TRIAL | ERLOTINIB | Receptor, ErbB-4 - metabolism | Receptor, ErbB-3 - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Male | Protein Kinase Inhibitors - adverse effects | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Paclitaxel - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Neoplasms - enzymology | Paclitaxel - adverse effects | Receptor, ErbB-3 - antagonists & inhibitors | Treatment Outcome | United Kingdom | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Maximum Tolerated Dose | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Receptor, ErbB-4 - antagonists & inhibitors | Neoplasms - pathology | Antimitotic agents | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 01/2017, Volume 483, Issue 1, pp. 58 - 63
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 02/2018, Volume 19, Issue 2, pp. 132 - 137
Journal Article
Journal Article
Inflammation, ISSN 0360-3997, 4/2017, Volume 40, Issue 2, pp. 387 - 400
Journal Article